Zobrazeno 1 - 10
of 82
pro vyhledávání: '"F. Salti"'
Autor:
Marco Pahor, Niccolò Marchionni, Giulio Masotti, Elisabetta Tonon, Marco Nardi, Andrea Ungar, C. De Fusco, F. Salti, Riccardo Pini, M. Di Bari
OBJECTIVE To define: (1) the prevalence of and (2) factors associated with undertreatment of hypertension in older persons; and (3) the prevalence of specific drug regimens and reasons for their selection. PARTICIPANTS Cross-sectional survey of perso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b860ac8a74880e8cd6442f2825dd2a1
http://hdl.handle.net/2158/308943
http://hdl.handle.net/2158/308943
Autor:
R, Tarquini, F, Perfetto, A, Zoccolante, F, Salti, A, Piluso, V, De Leonardis, V, Lombardi, G, Guidi, B, Tarquini
Publikováno v:
Anticancer research. 15(6B)
Melatonin (MEL), the main hormone produced by the pineal gland, seems to exert antineoplastic activity both in vitro and in vivo. Moreover, several studies reported increased melatonin blood levels in cancer patients. Plasma melatonin concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7793e3964a1ce9799ba26c0d07dc4bd0
https://pubmed.ncbi.nlm.nih.gov/8669838
https://pubmed.ncbi.nlm.nih.gov/8669838
Autor:
F. Salti, Roberto Caporale, Stefania Ciolli, Franco Leoni, Chiara Nozzoli, A. Pascarella, P. Rossi Ferrini, C. Marrani
Publikováno v:
Leukemialymphoma. 18(5-6)
The results of treatment with low dose cytosine arabinoside (LDARA-C) in 131 AML patients ineligible for standard regimens were analyzed retrospectively. Eighty-seven were previously untreated, 25 were refractory to conventional chemotherapy and 19 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7662cd4b3fcbb236bf389a7f8cb580d5
https://pubmed.ncbi.nlm.nih.gov/8528054
https://pubmed.ncbi.nlm.nih.gov/8528054
Autor:
Roberto Caporale, F. Salti, Franco Leoni, A. Pascarella, G. Giuliani, P. Rossi Ferrini, L. Cervi, S. Cioixi
Publikováno v:
British journal of haematology. 90(1)
AML in the elderly is characterized by intrinsic biological features implying an enhanced chemoresistance. Intensive chemotherapy should be the treatment of choice, but the standard doses could induce unacceptable rates of aplastic deaths. We evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c4f694c88e9fbc4cca3c486f279525
https://pubmed.ncbi.nlm.nih.gov/7786781
https://pubmed.ncbi.nlm.nih.gov/7786781
Publikováno v:
Haematologica. 78(3)
The expression of the CD34 antigen on the blast cells of acute myeloid leukemia (AML) has been regarded as an unfavorable prognostic factor for the achievement of complete remission (CR). However, clinical reports on this issue still remain controver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::660176445c83b0998cabe9c880e34209
https://pubmed.ncbi.nlm.nih.gov/8175042
https://pubmed.ncbi.nlm.nih.gov/8175042
Publikováno v:
Leukemialymphoma. 7(5-6)
Forty-three consecutive patients with refractory myeloma, median age 60, received monthly courses of teniposide 30 mg/m2 i.v. on days 1-2, dexamethasone 40 mg i.v. on days 1-7 and cyclophosphamide 200 mg/m2 by continuous i.v. infusion for seven days.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2900be393776b79ae09d10f6daa48543
https://pubmed.ncbi.nlm.nih.gov/1493448
https://pubmed.ncbi.nlm.nih.gov/1493448
Publikováno v:
Haematologica. 76(4)
Despite more aggressive salvage regimens, the prognosis of refractory acute lymphoblastic leukemia (ALL) is still poor. Hence, alternative approaches are warranted in heavily pretreated patients. Some studies suggest the enhancement of cyclophosphami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0036b396a7a5f0614ff4f93ab58ba81
https://pubmed.ncbi.nlm.nih.gov/1794736
https://pubmed.ncbi.nlm.nih.gov/1794736
Publikováno v:
British journal of haematology. 77(2)
Twenty-one patients with advanced refractory myeloma (nine primary unresponsive to melphalan, 12 relapsed and resistant to first-line salvage therapy) received monthly 7 d courses of cyclophosphamide by continuous infusion, associated with teniposide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3db317db06976527492cc48486848aec
https://pubmed.ncbi.nlm.nih.gov/2004019
https://pubmed.ncbi.nlm.nih.gov/2004019
Autor:
Franco Leoni, C. Marrani, F. Salti, P. Rossi Ferrini, Stefania Ciolli, Roberto Caporale, A. Pascarella, Chiara Nozzoli
Publikováno v:
European Journal of Cancer. 32:S14
In the aim of increase the response rate, we replaced VM-26 with idarubicin (IDA) or mitoxanlrone (MITOX) in a salvage regimen consisting of cyclophosphamide (CY) by continous iv infusion plus dexamethasone (DEX), previously reported by us as active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12c433fdabb5e5e698eb4ce81e7eefdb
https://doi.org/10.1016/0959-8049(96)84825-8
https://doi.org/10.1016/0959-8049(96)84825-8
Autor:
Giuseppe Papa, M. Soldani, S. Magro, G. D. Palka, T. Izzi, G. Nappi, Sante Tura, Alfonso Zaccaria, V. Rizzoli, C. Quarantelli, E. Lanzi, G. De Sandre, C. Carnevali, F. Salinas, G. Broccia, A. Cajozzo, C. A. Dinelli, L. Annino, Emma Cacciola, M. Gobbi, R. Buzzoni, A. Alberti, G. Panzacchi, E. Bajetta, Giovanna Corbelli, Luigi Gugliotta, L. Bruzzese, M. Bosisio, M. Fiacchini, Giovanni Pizzolo, P. Citarrella, F. De Cataldo, Rosario Giustolisi, T. Barbui, F. Leoni, M. Liberati, Franco Mandelli, Giuliana Alimena, A. Miliani, V. Raimondo, A. Manna, G. Lucarelli, S. Tura, Gianluigi Cetto, R Di Guglielmo, G. Guglielmi, R. Musso, F. Grignani, E. Dini, P. Ricci, A. Delsignore, S. Monjardini, A. Abbadessa, P. Di Marco, F. Salti, Francesco Lauria, A. Bonati, L. Geraci, M. Baccarani, Michele Baccarani, P. Rossi Ferrini, G. Corbelli, A. Porcellini, M. Tonato, G. Torlontano, P. Sansoni, G. Perona, A. Allegra, M. F. Martelli, R. Battista
Publikováno v:
Leukemia Research. 5:149-157
The effect of early splenectomy and of polychemotherapy with hydroxyurea, busulfan, and alternate bimonthly courses of arabinosyl cytosine and vincristine plus prednisone, was evaluated in 139 previously untreated patients with chronic myeloid leukem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b645481f359f6a534d1e604bd45f1bb
https://doi.org/10.1016/0145-2126(81)90073-4
https://doi.org/10.1016/0145-2126(81)90073-4